Prof. Farhad Hafezi
July 13, 2023
Switzerland, particularly Zurich, has been a leader in corneal cross-linking (CXL) research and innovation for over two decades, explained ELZA’s Medical Director, Prof. Farhad Hafezi,
ELZA’s Medical Director, Prof. Farhad Hafezi has returned from Antalya, Turkey, where he gave a lecture entitled “Frontiers in Cross-Linking in Keratoconus” to the delegates of the
It has been quite the debate. Should surgeons drop riboflavin onto the cornea during the UV irradiation part of a corneal cross-linking (CXL) procedure, or
The ELZA team of surgeons and researchers were all in attendance, and today saw Prof. Hafezi give the attending delegates a lecture on “How to treat thin corneas”, where he examined the history of performing corneal cross-linking (CXL) for the treatment of corneal ectasias like keratoconus. He then brought delegates up-to-date on the research that has been performed over the years to improve how thin corneas are cross-linked. Finally, Prof. Hafezi demonstrated the results of the latest thin cornea cross-linking protocol, sub400, developed by ELAZA, which simplifies the process, and can let surgeons, for the first time, cross-link corneas that are as thin as 200 µm.
